surmount-1 tirzepatide weight loss nondiabetic trial obesity without diabetes non-diabetic In an earlier analysis of the trial, (a dual surmount-1 tirzepatide non-diabetic obesity trial – Semaglutide vs. Tirzepatide for Obesity

These can often be mitigated by eating small, bland meals, increasing hydration, and avoiding high-fat and high-sugar foods

However, they can only detect existing problems rather than future risks

While Semaglutide helps control hunger , long-term success depends on lifestyle changes

Injectable weight-management therapies may be discussed for individuals experiencing: Difficulty losing weight despite diet and exercise Weight-loss plateaus Slower metabolism Increased appetite or frequent cravings The need for additional support during a weight-loss program A consultation helps determine which approach may best support your individual needs